menu search

OCTHF / Oxford Cannabinoid Technologies issues positive trading and operational update

Oxford Cannabinoid Technologies issues positive trading and operational update
Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) (OCTP), which is developing prescription cannabinoid medicines targeting the pain market, has issued a positive trading and operational update for the six months ended 31 October 2022. In the statement, Clarissa Sowemimo-Coker, Interim CEO of OCTP, said: "We are incredibly pleased with the ongoing progress and the fact that we remain on track to meet our financial and operational targets. Read More
Posted: Dec 12 2022, 02:46
Author Name: Proactive Investors
Views: 102446

OCTHF News  

Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug

By Proactive Investors
October 24, 2023

Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug

Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid Technologies Holdings, discusses with Proactive's Thomas Warner the successful completion of a phas more_horizontal

Oxford Cannabinoid Technologies shares jumo 6% on successful completion of phase I study

By Proactive Investors
October 10, 2023

Oxford Cannabinoid Technologies shares jumo 6% on successful completion of phase I study

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) rose 6% following the successful completion of the phase I study for its more_horizontal

Oxford Cannabinoid readies for next stage as it safely navigates phase I stduy

By Proactive Investors
October 10, 2023

Oxford Cannabinoid readies for next stage as it safely navigates phase I stduy

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) hailed as a 'major milestone' the successful completion of dosing for all cohorts more_horizontal

Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset

By Proactive Investors
September 25, 2023

Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has successfully administered the final dose of its lead drug candidate, OCT46120 more_horizontal

Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track

By Proactive Investors
August 31, 2023

Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) hailed a “defining year” for the progress of its leading drug candidates and more_horizontal

Oxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expert

By Proactive Investors
July 27, 2023

Oxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expert

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) said it has commenced its phase I clinical trial for the lead drug candidate, OC more_horizontal

Oxford Cannabinoid jumps as firm hints cheaper cancer treatments

By Proactive Investors
July 17, 2023

Oxford Cannabinoid jumps as firm hints cheaper cancer treatments

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) rose 10% on Monday as the pharmaceutical company formally announced its more_horizontal

Oxford Cannabinoid expands into oncology with potential new cannabinoid-based treatment

By Proactive Investors
July 17, 2023

Oxford Cannabinoid expands into oncology with potential new cannabinoid-based treatment

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), a pharmaceutical company specialising in prescription cannabinoid medicines, is more_horizontal


Search within

Pages Search Results: